Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Braich, Ted; Ahmann, Frederick R.; Garewal, Harinder S.; Robertone, Aurelia; Salmon, Sydney E.

doi:10.1007/bf00194602

Cited by 12 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase II clinical trials using esorubicin in a variety of tumors have now been completed [1,[5][6][7][8][9][10][11]. Although modest clinical activity has been reported in malignant lymphoma [5] and breast cancer [11], other clinical reports have been disappointing.…”

Section: Discussionmentioning

confidence: 99%

“…Based on in vitro and animal data, esorubicin appeared to possess a broader spectrum of clinical activity and less myocardial toxicity than doxorubicin [2][3][4]. Several studies have described the drug's antitumor activity in patients with advanced cancer [5][6][7][8][9][10][11] with the suggestion that clinical and subclinical myocardial toxicity may occur in human subjects [12][13][14]. We report the cardiotoxicity observed from esorubicin in two phase II clinical trials conducted by the Cancer and Leukemia Group B (CALGB) [6,71.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases

et al. 1990

View full text Add to dashboard Cite

Esorubicin (4'-deoxydoxorubicin, DxDx) has undergone extensive Phase II investigation for the treatment of cancer. Based on in vitro and animal data, esorubicin may possess less myocardial toxicity when compared to doxorubicin. One hundred thirty-six patients with histologically or cytologically documented non-small cell lung cancer or advanced breast cancer were enrolled in two concurrent CALGB clinical trials using esorubicin at a dose of 30 mg/m2 administered intravenously every 21 days. No patient had previously received an anthracycline agent or had evidence of severe cardiovascular disease. Cardiotoxicity was observed in eleven patients. Four patients developed symptoms of congestive heart failure and three asymptomatic patients had a significant fall in left ventricular ejection fraction (LVEF) as measured by gated pool heart scan. Four patients had cardiac signs or symptoms of indeterminate relationship to esorubicin therapy. Of 44 patients receiving more than four cycles of therapy, 36 patients (82%) had serial gated pool heart scans permitting assessment of subclinical myocardial toxicity. A 5% drop in LVEF was observed following approximately 240 mg/m2 esorubicin; a 10% drop was observed after approximately 480 mg/m2. If further clinical studies are undertaken with esorubicin, investigators are advised to monitor cardiac function frequently once the cumulative esorubicin dose exceeds 240 mg/m2. If congestive failure appears during therapy, prompt cessation of esorubicin and institution of inotropic agents may provide effective palliation. Normal myocardial function may be restored within several months.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases

et al. 1990

View full text Add to dashboard Cite

show abstract

“…Phase II trials demonstrated some activity for esorubicin in colorectal cancer, breast cancer and multiple myeloma [8][9][10]. No activity was noted in trials of non-small cell lung cancer, melanoma, renal cell carcinoma, prostate cancer, or head and neck cancer [11][12][13][14][15]. As more experience with the drug was accumulated, evidence of cardiotoxic effects were noted [16].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study

McGuire¹,

Blessing

Yordan

et al. 1989

Invest New Drugs

View full text Add to dashboard Cite

Twenty-eight patients with advanced, measurable squamous carcinoma of the uterine cervix were treated with 62 courses of esorubicin at doses ranging from 20-35 mg/m2 every three weeks. All patients were evaluable for response and toxicity. All patients had received prior therapy including radiation therapy in 28, chemotherapy in 23, and surgery in 11. All patients were Gynecologic Oncology Group (GOG) performance status 0, 1 or 2. There were no responses seen. Severe (grade 3 or 4) leukopenia, thrombocytopenia, and anemia were seen in 13, 3, and 9 patients, respectively. Gastrointestinal toxicity as well as alopecia were the other adverse effects. Mucositis and phlebitis were not seen. Neither clinical congestive cardiomyopathy nor decrement in left ventricular ejection fraction was observed. Lack of response in association with moderate toxicity using this dose and schedule of esorubicin in squamous carcinoma of the cervix previously treated with chemotherapy makes further study as a salvage agent unwarranted.

show abstract

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

Yagoda¹,

Petrylak²

1993

Cancer

404

171

View full text Add to dashboard Cite

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Cited by 12 publications

References 8 publications

Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases

Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases

Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

Contact Info

Product

Resources

About